Trending...
- AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
- New Mobile Car Detailing Platform Connects Drivers with On-Demand Local Pros
- Cal State LA secures funding for two artificial intelligence projects from CSU
SAN JOSE, Calif., Dec. 11, 2019 /PRNewswire/ -- Anpac Bio-Medical Science Co., Ltd. ("Anpac Bio" or the "Company") announced today the appointment of Professor Michael Levitt of Stanford University to be the Chief Consultant of Anpac Bio's Innovation and Technical Advisory Board. Dr. Levitt received the 2013 Nobel Prize in Chemistry for the development of multiscale models for complex chemical systems. Dr. Levitt's role will be to help strengthen Anpac Bio's patented CDA (Cancer-Differentiation Analysis) technology, which can detect the risk of up to 26 cancer types using a single blood test. Anpac Bio provides its CDA tests commercially in China and is currently working to enter the market in the United States.
Anpac Bio's Chairman and CEO, Chris Yu, commented, "Anpac is excited to be working with Dr. Levitt on our ground-breaking technology. Our innovative biophysical approach to cancer screening and detection is complementary with Dr. Levitt's background in quantum mechanics, chemistry, and structural biology. We believe that Dr. Levitt's contributions will help us to achieve further market penetration in China and will assist us in our entrance in the United States through clinical trials and additional academic collaborations."
More on The Californer
Dr. Levitt has previously served on the Scientific Advisory Boards of DuPont Merck Pharmaceuticals, AMGEN, PDL Biopharma, as well as many other well-known companies throughout his career. Dr. Levitt received his PhD from Cambridge University in 1972 and was a postdoctoral scholar at the Weizmann Institute of Science in Israel from 1972 to 1974. Dr. Levitt joined the Department of Structural Biology at Stanford in 1987.
About Anpac Bio
Anpac Bio is a biotechnology company focused on early cancer screening and detection. With two certified clinical laboratories in China, Anpac Bio performs a suite of cancer screening and detection tests, including CDA, bio-chemical, immunological, and genomics tests. In a recent market research report by Frost & Sullivan, Anpac Bio ranked second worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 35,000 clinical samples as at June 30, 2019. These clinical samples demonstrated that Anpac Bio's CDA technology could detect the risk of over 20 different cancer types with high sensitivity and specificity. https://www.anpacbio.com/
More on The Californer
Safe Harbor Statement
This announcement contains forward-looking statements, including statements about the Company's business outlook, strategy and market opportunity, and statements that may suggest trends for its business. These statements are individually and collectively forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made only as of the date of this announcement and are based on estimates and information available to the Company at the time of this announcement. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict and may be beyond the Company's control. Therefore, prospective investors are cautioned that actual results may differ materially from those set forth in any forward-looking statements herein. Except as otherwise required by applicable securities laws, the Company disclaims any intention or obligation to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE AnPac Bio-Medical Science Co., Ltd.
Related Links
https://www.anpacbio.com
Anpac Bio's Chairman and CEO, Chris Yu, commented, "Anpac is excited to be working with Dr. Levitt on our ground-breaking technology. Our innovative biophysical approach to cancer screening and detection is complementary with Dr. Levitt's background in quantum mechanics, chemistry, and structural biology. We believe that Dr. Levitt's contributions will help us to achieve further market penetration in China and will assist us in our entrance in the United States through clinical trials and additional academic collaborations."
More on The Californer
- Fastest Growing Staffings Firms
- Inframark Continues to Build Its Community Management Capabilities and Multi-Disciplinary Presence in Arizona
- ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
- Rachel Farris, CPA Featured on The AJ Brown Show to Discuss Act 60 Tax Incentives
- Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
Dr. Levitt has previously served on the Scientific Advisory Boards of DuPont Merck Pharmaceuticals, AMGEN, PDL Biopharma, as well as many other well-known companies throughout his career. Dr. Levitt received his PhD from Cambridge University in 1972 and was a postdoctoral scholar at the Weizmann Institute of Science in Israel from 1972 to 1974. Dr. Levitt joined the Department of Structural Biology at Stanford in 1987.
About Anpac Bio
Anpac Bio is a biotechnology company focused on early cancer screening and detection. With two certified clinical laboratories in China, Anpac Bio performs a suite of cancer screening and detection tests, including CDA, bio-chemical, immunological, and genomics tests. In a recent market research report by Frost & Sullivan, Anpac Bio ranked second worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 35,000 clinical samples as at June 30, 2019. These clinical samples demonstrated that Anpac Bio's CDA technology could detect the risk of over 20 different cancer types with high sensitivity and specificity. https://www.anpacbio.com/
More on The Californer
- Jade & Zelda Launch Virtually Human: A Groundbreaking Podcast Hosted by AI-Powered Virtual Humans
- Dr. Satyam Priyadarshy Joins Indemnify AI to Enrich AI Risk Financial Quantification
- $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
- Fact: Trump lied — again. California gas prices remain lower than a week ago, month ago, and a year ago
- Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
Safe Harbor Statement
This announcement contains forward-looking statements, including statements about the Company's business outlook, strategy and market opportunity, and statements that may suggest trends for its business. These statements are individually and collectively forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made only as of the date of this announcement and are based on estimates and information available to the Company at the time of this announcement. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict and may be beyond the Company's control. Therefore, prospective investors are cautioned that actual results may differ materially from those set forth in any forward-looking statements herein. Except as otherwise required by applicable securities laws, the Company disclaims any intention or obligation to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE AnPac Bio-Medical Science Co., Ltd.
Related Links
https://www.anpacbio.com
Filed Under: Business
0 Comments
Latest on The Californer
- TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
- Revolutionary conversational AI transforms customer engagement with professional virtual receptionist answering service tailored for small busines
- New AI platform helps small businesses deliver always-available, professional customer service without added staff or complexity
- VoiceGenie AI empowers small businesses with 24/7, brand-driven customer engagement through an AI-powered virtual front desk receptionist
- California: Governor Newsom signs tribal-state gaming compact 7.14.25
- VoiceGenie AI empowers small businesses with human-like call answering and customer engagement—bridging the gap between automation and live
- New 24/7 AI solution transforms customer engagement and efficiency for small businesses seeking live virtual receptionist services
- Next-generation virtual receptionist service leverages AI to ensure every customer call and text is answered, enhancing efficiency and engagem
- Next-Gen AI Receptionist Elevates Customer Communication, Boosts Efficiency for Small Businesses
- California: Governor Newsom signs legislation 7.14.25
- New AI-Powered Platform from Kell Web Solutions Delivers 24/7 Professional, Automated Call Handling and Appointment Scheduling
- Kell Web Solutions Launches Next-Gen VoiceGenie AI Call Answering Service for Businesses
- 24/7 Conversational AI Platform Raises the Standard for Small Business Customer Engagement
- Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
- QuickLogic Announces the Passing of Board Director Christine Russell
- KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
- IEI USA Launches SHIELD Rugged Stainless Steel Panel PCs for Hygiene-Critical Industries
- In historic first, California powered by two-thirds clean energy – becoming largest economy in the world to achieve milestone
- North Island Credit Union Foundation Provides $5,000 in Teacher Grants To Benefit Educators & Students
- The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison